An exclusive conversation with OpenAI’s chief scientist, Jakub Pachocki, about his firm's new grand challenge and the future ...

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Sorry to burst your bubble right off the bat, but the show hasn’t even been renewed yet. While Welcome to Derry had a strong start, that number quickly fell off in subsequent episodes. That said, it’s ...

Draper took to X, sharing his recent interview on the Founders Room Podcast, in which he talked about the increasing dominance of Bitcoin in the blockchain space. “I think there’s a gravitational pull ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The last time I spoke about Replimune (REPL) it was with respect to a Seeking Alpha article entitled "Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma." With respect to this ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

Replimune (NASDAQ:REPL) announced on Tuesday that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding its marketing application for its lead asset, RP1, declining ...

Multiple analysts have issued price targets for $REPL recently. We have seen 4 analysts offer price targets for $REPL in the last 6 months, with a median target of ...